Related Experiment Video
Updated: Apr 12, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Acute renal failure after treatment with sunitinib in a patient with multiple myeloma
Nelson Leung1, Nathan A Saucier1, Steven R Zeldenrust2
1Division of Nephrology and Hypertension.
Abstract:
Sunitinib is a multiple tyrosine kinase receptors inhibitor that is approved for the treatment of advanced renal cell carcinoma. Amongst its targets are fetal liver tyrosine kinase receptor 3 (FLT 3) and vascular endothelial growth factor receptor (VEGFR). Renal toxicity has not been reported from the trials, but several patients have been reported to develop a pre-eclampsia-like syndrome. We report the first case of acute tubular necrosis in a patient with multiple myeloma following treatment with sunitinib.
Insights
Sunitinib, a cancer drug, can cause kidney damage. This report details the first case of acute tubular necrosis, a severe kidney injury, in a multiple myeloma patient treated with sunitinib.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Sunitinib is an oral multi-targeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma.
- Its known targets include fetal liver tyrosine kinase receptor 3 (FLT3) and vascular endothelial growth factor receptor (VEGFR).
- While clinical trials did not report renal toxicity, some patients developed a pre-eclampsia-like syndrome.
Observation:
- A patient with multiple myeloma was treated with sunitinib.
- The patient developed acute tubular necrosis.
Findings:
- This is the first reported case of acute tubular necrosis in a multiple myeloma patient receiving sunitinib.
- The mechanism linking sunitinib to acute tubular necrosis in this context requires further investigation.
Implications:
- This case highlights a potential, previously unreported renal adverse effect of sunitinib.
- Clinicians should be vigilant for renal toxicity, including acute tubular necrosis, in multiple myeloma patients treated with sunitinib.
- Further research is warranted to elucidate the pathophysiology and incidence of sunitinib-induced acute tubular necrosis.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
05:34A Mouse Model to Evaluate the Long-Term Structural and Functional Outcomes after the Reversal of Prolonged Unilateral Ureteric Obstruction
Published on: July 18, 2025
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management